RT Journal Article
SR Electronic
T1 Temporal changes in SARS-CoV-2 clearance kinetics and the optimal design of phase 2 antiviral studies
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.01.16.24301342
DO 10.1101/2024.01.16.24301342
A1 Wongnak, Phrutsamon
A1 Schilling, William HK
A1 Jittamala, Podjanee
A1 Boyd, Simon
A1 Luvira, Viravarn
A1 Siripoon, Tanaya
A1 Ngamprasertchai, Thundon
A1 Batty, Elizabeth M
A1 Singh, Shivani
A1 Kouhathong, Jindarat
A1 Pagornrat, Watcharee
A1 Khanthagan, Patpannee
A1 Hanboonkunupakarn, Borimas
A1 Poovorawan, Kittiyod
A1 Mayxay, Mayfong
A1 Chotivanich, Kesinee
A1 Imwong, Mallika
A1 Pukrittayakamee, Sasithon
A1 Ashley, Elizabeth A
A1 Dondorp, Arjen M
A1 Day, Nicholas PJ
A1 Teixeira, Mauro M
A1 Piyaphanee, Watcharapong
A1 Phumratanaprapin, Weerapong
A1 White, Nicholas J
A1 Watson, James A
A1 the PLATCOV Collaborative Group
YR 2024
UL http://medrxiv.org/content/early/2024/01/17/2024.01.16.24301342.abstract
AB Background Effective antiviral drugs prevent hospitalisation and death in COVID-19. Antiviral efficacy can be assessed efficiently in-vivo by measuring rates of SARS-CoV-2 clearance estimated from serial viral densities measured in nasopharyngeal or oropharyngeal swab eluates. The changing epidemiology of SARS-CoV-2 infection has substantially affected viral clearance kinetics and thus the optimal design and interpretation of antiviral pharmacometric evaluations.Methods Serial viral density data were analysed from patients enrolled in a large multicentre randomised adaptive pharmacodynamic platform trial (PLATCOV) comparing antiviral interventions for SARS-CoV-2. Viral clearance rates over one week were estimated and boot-strap re-sampling was used to assess the optimal duration of follow-up for pharmacometric assessment, where optimal is defined as maximising the expected z-score.Results Between 29 September 2021 and 20 October 2023, 1264 patients were randomised. Unblinded data were available from 800 patients (16,818 oropharyngeal viral qPCR measurements). SARS-CoV-2 viral clearance was biphasic (bi-exponential). The first phase (α) was accelerated by effective interventions. For all the effective interventions studied, maximum discriminative power (maximum expected z-score) was obtained when evaluating serial data from the first 5 days after enrolment. Over the two year period studied, median viral clearance half-lives estimated over 7 days have shortened from 16.8 hours in September 2021 to 9.3 hours in October 2023 in patients receiving no antiviral drugs, equivalent to a relative reduction of 44% [95% credible interval (CrI): 17 to 67%]. A parallel trend was observed in treated patients. In the ritonavir-boosted nirmatrelvir arm the median clearance half-life declined from 6.6 hours in June 2022 to 4.8 hours in October 2023, a relative reduction of 26% [95%CrI: -4 to 42%].Conclusions SARS-CoV-2 viral clearance kinetics in symptomatic vaccinated individuals have accelerated substantially over the past two years. Antiviral efficacy in COVID-19 can now be assessed efficiently in-vivo using serial qPCRs from duplicate oropharyngeal swab eluates taken daily for 5 days after drug administration.Funding Wellcome Trust Grant ref: 223195/Z/21/Z through the COVID-19 Therapeutics Accelerator.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNCT05041907Funding StatementThis study is supported by Wellcome Trust grant reference 223195/Z/21/Z through the COVID-19 Therapeutics Accelerator.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The trial was approved by the Oxford University Tropical Research Ethics Committee (Oxford, UK) and ethics committees in each country. The results were reviewed regularly by a data and safety monitoring board. In Thailand the trial was approved by the Faculty of Tropical Medicine Ethics Committee, Mahidol University, (reference TMEC 21-058); in Brazil by the Research Ethics Committee of the Universidade Federal de Minas Gerais (COEP-UFMG, Minas Gerais, Brazil, COEP-UFMG) and National Research Ethics Commission- (CONEP, Brazil, COEP-UFMG and CONEP Ref: CAAE:51593421.1.0000.5149); in Laos by the National Ethics Committee for Health Research (NECHR, Lao PDR, Submission ID 2022.48) and the Food & Drugs Department (FDD, Lao PDR, 13066/FDD_12Dec2022); in Pakistan by the National Bioethics Committee (NBC No.4-87/COVID-111/22/842) the Ethics Review Committee (ERC 2022-7496-21924) and the Drug Regulatory Authority (DRAP Ref: No.03-18/2022-CT (PS)).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data and code necessary to reproduce the results in this analysis are openly available at https://github.com/jwatowatson/Determinants-viral-clearance https://github.com/jwatowatson/Determinants-viral-clearance